Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type 2 diabetes and chronic kidney disease, Novo Nordisk said.
Bagsværd, Denmark, 17 January 2025 – Novo Nordisk today announced headline results from STEP UP, a phase 3b trial in the ...
HealthDay on MSN13d
Semaglutide Doubles Risk for Nonarteritic Anterior Ischemic Optic NeuropathyHealthDay News — Use of once-weekly semaglutide more than doubles the risk for nonarteritic anterior ischemic optic neuropathy (NAION) in individuals with type 2 diabetes, according to a study ...
President-elect Trump’s threat to tariff Denmark if it resists his acquisition plans for the island territory of Greenland ...
A safety committee will review all evidence from trials and studies to shed more light on the potential risk of NAION.
Kidney disease treatment is undergoing a transformation, driven by exciting new research that reveals the protective power of semaglutide in patients with type 2 diabetes. Semaglutide, a ...
Semaglutide, sold under the brand names of Ozempic, Rybelsus and Wegovy, is one of the most popular drugs on the market.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback